Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.

Linus A Völker Paul Thomas Brinkkoetter Paul N KnöblMiroslav KrsticJessica KaufeldJan Menne Veronika Buxhofer-AuschWolfgang Miesbach

Published in: Journal of thrombosis and haemostasis : JTH (2020)

In conclusion, in selected cases of acute bouts of aTTP, it seems feasible to delay or omit plasma exchange if platelet counts increase and organ function is stable after start of caplacizumab therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
liver failure
peritoneal dialysis
prognostic factors
respiratory failure
intensive care unit
extracorporeal membrane oxygenation
patient reported
replacement therapy